ESC: AstraZeneca's SGLT2 med Farxiga flips script on competitors with 26% CV risk cut

AstraZeneca’s diabetes med Farxiga is still looking for the cardiovascular label updates its SGLT2 competitors already bear. But as of this weekend, it has new data that could help the entire class—and even pressure heart medicines outside the class, too.